fter receiving intravenous immunoglobulin (IVIg) to treat chronic inflammatory demyelinating polyneuropathy (CIDP) for nearly 20 years, Christina Caron heard about a recent immunoglobulin shortage via social media.
Early intervention is the key to minimizing disability for patients with chronic inflammatory demyelinating polyneuropathy (CIDP), and data from several recent studies support the monoclonal anti-CD20 antibody rituximab as a possible treatment when first-line treatments are not effective.
Assessing grip strength may be a viable way to optimize intravenous immune globulin (IVIg) treatments in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), suggests results from the small, prospective, observational GRIPPER study presented at the annual meeting of the American Association for Neuromuscular and Electrodiagnostic Medicine in Austin, Tex.
CIDP trials pursue treatment biomarkers, but clinical expertise in diagnosis, treatment remains shaky
Chronic inflammatory demyelinating polyneuropathy (CIDP) can be a difficult condition for neurologists to navigate, and yet most clinicians may be failing to follow current standards for diagnosis and treatment, based on a nationwide survey.